$CRL

Parisotto Shannon M sold $1.0M of CRL

Parisotto Shannon M (CEVP, Disc & Safety Assessment) sold 3,714 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $279.66 ($1.04M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parisotto Shannon M
Published Aug 13, 2026, 8:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CRL
Neutral
high confidence
Mentioned
$CRL
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CRLNeutralLow
01

Why it matters

The disclosed event is an open-market sale by an officer under a pre-arranged 10b5-1 plan, which is generally treated as routine compliance rather than a new fundamental catalyst.

02

Market read

Traders may log the sale for sentiment monitoring, but it is unlikely to drive a material repricing without accompanying company-specific news.

03

What to watch

The article provides no context on total insider holdings beyond post-transaction shares, no explanation for the sale, and no concurrent company news, limiting signal strength.

Relevance 5/10Novelty 3/10Timing: filed Aug 13, transaction dated Aug 11

Background

This is an SEC Form 4 insider transaction disclosure for Charles River Laboratories International, Inc. (CRL).

Company-level read

Ticker impact

$CRLNeutralHigh confidence
Context

CRL insider Parisotto Shannon M sold 3,714 shares for about $1.04M under a pre-arranged 10b5-1 plan filed on SEC EDGAR.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 open-market sale by an officer with an explicit pre-arranged 10b5-1 plan, which reduces interpretive value versus discretionary selling.

Market effects

No clear sector read-through from a single routine insider sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so traders may watch for follow-on sales or changes in buying activity.

Key entities

  • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Parisotto Shannon M

    Officer (CEVP, Disc and Safety Assessment) who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACBHighAI 8/10

Aurora Snipes Back At Curaleaf’s Hostile Bid

Aurora Cannabis rejected Curaleaf's hostile $4 per share bid, urging shareholders to take no action. Curaleaf claims its offer represents a 45% premium over Aurora's 30-day average share price. Aurora's shares rose 34% to $3.89, while Curaleaf's OTC shares gained 6% to $9.80. Aurora's board formed a special committee to review the offer, which expires on December 1.

$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

$CRLMed

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

Charles River Laboratories (CRL) reported Q2 2026 results, citing a strengthening biopharmaceutical demand environment. DSA net book-to-bill rose to nearly 1.2x for a third straight quarter above 1x. Organic revenue growth returned to 0.1%. Operating margin improved 420 bps sequentially to 20.5% after divestitures. CRL also announced collaborations with Eli Lilly (TuneLab) and Arovella Therapeutics (NGS).

$CRLMed

Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?

Charles River Laboratories International (CRL) cut its 2026 GAAP earnings guidance and reported a quarterly net loss, citing divestiture-related charges and slightly lower revenue year over year. The article notes strong recent share performance and presents two valuation views, including a $313.61 fair value versus a $267.49 last close, plus a planned $510M acquisition of K.F. (Cambodia) Ltd.

$CRLMed

Charles River (CRL) Lifts Adjusted EPS Outlook After DSA Beat and Divestiture Hit Has The Bull Case Changed?

Charles River Laboratories (CRL) reported Q2 2026 revenue of $1,004.08M and a GAAP net loss of $1.48M. The company cut 2026 GAAP EPS guidance to $3.05 to $3.35 per share due to divestiture-related losses, but raised full-year adjusted (non-GAAP) EPS after DSA results beat expectations, citing margin potential and lower non-human primate sourcing costs.